Prostate small cell carcinoma

Summary

Prostate small cell carcinoma (MONDO:0006390) is a cancer and 10 clinical trials. Top therapeutic interventions include cabozantinib, cabazitaxel, and erdafitinib. A subtype of small cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prostate small cell carcinoma
Mondo ID	MONDO:0006390
EFO	EFO:1000499
DOID	DOID:7141
NCIT	C6766
SNOMED CT	396198006
UMLS	C1300585
MedGen	266251
GARD	0024395
Anatomy (UBERON)	UBERON:0002367
Is cancer (heuristic)	yes

Also known as: Oat cell carcinoma of prostate · Oat cell carcinoma of the prostate · prostate gland small cell carcinoma · prostate Oat cell carcinoma · prostate oat cell carcinoma · prostate small cell carcinoma · prostate small cell NEC · prostate small cell neuroendocrine carcinoma · PRSCC · small cell carcinoma of prostate · small cell carcinoma of prostate gland · small cell carcinoma of the prostate

Data availability: 5 cell lines.

Disease family

This is a subtype of small cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › neuroendocrine carcinoma › small cell carcinoma › prostate small cell carcinoma

Related subtypes (17): extrahepatic bile duct small cell adenocarcinoma, ovarian small cell carcinoma, colon small cell neuroendocrine carcinoma, urinary bladder small cell neuroendocrine carcinoma, esophageal small cell neuroendocrine carcinoma, ampulla of vater small cell neuroendocrine carcinoma, Bartholin gland small cell carcinoma, thymus small cell carcinoma, cervical small cell carcinoma, endometrial small cell carcinoma, gallbladder small cell neuroendocrine carcinoma, gastric small cell neuroendocrine carcinoma, laryngeal small cell carcinoma, pancreatic small cell neuroendocrine carcinoma, salivary gland small cell carcinoma, ureter small cell carcinoma, small cell lung carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	7
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03866382	PHASE2	RECRUITING	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT04471974	PHASE2	ACTIVE_NOT_RECRUITING	ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT04592237	PHASE2	ACTIVE_NOT_RECRUITING	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
NCT05691465	PHASE2	RECRUITING	Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
NCT05969860	PHASE2	RECRUITING	At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT01505868	PHASE1/PHASE2	COMPLETED	Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
NCT03649841	PHASE2	TERMINATED	Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
NCT04754425	PHASE2	TERMINATED	Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
NCT03582475	PHASE1	ACTIVE_NOT_RECRUITING	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
NCT06094842	PHASE1	WITHDRAWN	Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	3
CABAZITAXEL	4	2
ERDAFITINIB	4	1
LUTETIUM OXODOTREOTIDE LU-177	4	1
NIRAPARIB	4	1
CETRELIMAB	3	1
ZEN-3694	2	1